Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics | Enterpreneurship

Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH.

Through its South San Francisco, CA-based Genentech division, the Swiss pharmaceutical giant will acquire Jecure, whose work has yet to reach clinical studies, the companies announced Tuesday. No financial terms were disclosed, but a Genentech spokesman said it was an all-cash deal.

Nonalcoholic steatohepatitis, or NASH, is a serious form of fatty liver disease that causes inflammation and scarring in the organ. There are no FDA-approved drugs for NASH, and in cases where the condition… Read more »

Reprints | Share:

UNDERWRITERS AND PARTNERS